Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | HMGCR | P04035 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | RGS12 | O14924 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8144830 | 0.84 | PTGS1 (0.36) | PTGS2PTGS1CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL6738999 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2HTTMEN1KMT2AGALR3 | |
| SCHEMBL6731121 | 0.81 | ALOX5 (0.34) | L3MBTL1GPR55NPSR1GAA | |
| SCHEMBL6738995 | 0.81 | MEN1 (0.45) | SMN1; SMN2HTTMEN1KMT2AGALR3 | |
| SCHEMBL6269589 | 0.77 | SMN1; SMN2 (0.50) | SMN1; SMN2HTTMEN1KMT2AGALR3 | |
| SCHEMBL8141137 | 0.75 | TDP1 (0.46) | KMT2AL3MBTL1ALDH1A1LMNAGAA | |
| SCHEMBL8414020 | 0.74 | TYR (0.36) | HTTMEN1KMT2AL3MBTL1PTGS2 | |
| SCHEMBL15299843 | 0.70 | HTT (0.46) | SMN1; SMN2HTTMEN1KMT2AGABBR2 | |
| SCHEMBL6071609 | 0.70 | HTT (0.46) | SMN1; SMN2HTTMEN1KMT2AGABBR2 | |
| SCHEMBL6154475 | 0.69 | PTGS2 (0.43) | SMN1; SMN2HTTMEN1KMT2APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2004-10-21 | — | — | US | claimed |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002065993-A2 | USE OF ARYL NITRONE COMPOUNDS IN METHODS FOR TREATING NEUROPATHIC PAIN | CENTAUR PHARMACEUTICALS, INC. (US) | 2002-08-29 | — | — | WO | claimed |
| EP-0724565-A1 | NOVEL SPIN TRAP NITRONYL HINDERED PHENOLS | Oklahoma Medical Research Foundation (US) | 1996-08-07 | — | — | EP | claimed |
| US-5527828-A | Spin trap nitronyl hindered phenols | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1996-06-18 | — | — | US | claimed |
| WO-1995011227-A1 | NOVEL SPIN TRAP NITRONYL HINDERED PHENOLS | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1995-04-27 | — | — | WO | claimed |
| US-8466319-B2 | Preparation of nitrones | ROHM AND HAAS COMPANY (US) | 2013-06-18 | — | — | US | disclosed |
| US-8461387-B2 | Preparation of nitrones | ROHM AND HAAS COMPANY (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130072721-A1 | PREPARATION OF NITRONES | ROHM AND HAAS COMPANY (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130065806-A1 | PREPARATION OF NITRONES | ROHM AND HAAS COMPANY (US) | 2013-03-14 | — | — | US | disclosed |
| US-8329949-B2 | Preparation of nitrones | ROHM AND HAAS COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2060561-B1 | Preparation Of Nitrones | ROHM & HAAS (US) | 2011-07-06 | — | — | EP | disclosed |
| US-20090126263-A1 | Preparation of nitrones | ROHM AND HAAS COMPANY | 2009-05-21 | — | — | US | disclosed |
| US-5527828-A | Spin trap nitronyl hindered phenols | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1996-06-18 | — | — | US | disclosed |
| US-5527828-A | Spin trap nitronyl hindered phenols | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1996-06-18 | — | — | US | disclosed |
| US-5455272-A | Free radical-scavenging antioxidant; cytoprotective agents, antiischemic agents | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1995-10-03 | — | — | US | disclosed |
| US-5455272-A | Free radical-scavenging antioxidant; cytoprotective agents, antiischemic agents | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1995-10-03 | — | — | US | disclosed |
| WO-1995011227-B1 | NOVEL SPIN TRAP NITRONYL HINDERED PHENOLS | — | 1995-05-18 | — | — | WO | disclosed |
| WO-1995011227-A1 | NOVEL SPIN TRAP NITRONYL HINDERED PHENOLS | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1995-04-27 | — | — | WO | disclosed |
| WO-1995011227-A1 | NOVEL SPIN TRAP NITRONYL HINDERED PHENOLS | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1995-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | OPRL1, OPRK1, OPRD1 | SMN1; SMN2 20/4885HTT 1120/4885MEN1 4651/4885 |
| US-20090126263-A1 | Preparation of nitrones | NOS2, NOS1, CBR1 | SMN1; SMN2 685/4885HTT 3281/4885MEN1 1351/4885 |
| US-20130072721-A1 | PREPARATION OF NITRONES | NOS2, NOS1, CBR1 | SMN1; SMN2 685/4885HTT 3281/4885MEN1 1351/4885 |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | OPRL1, OPRD1, OPRK1 | SMN1; SMN2 13/4885HTT 1060/4885MEN1 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.